Published in Ann Rheum Dis on February 01, 2001
The mammalian exosome mediates the efficient degradation of mRNAs that contain AU-rich elements. EMBO J (2002) 4.13
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med (2005) 2.82
Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) (2010) 1.99
Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry (2002) 1.84
The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis (2007) 1.66
Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis (2006) 1.54
Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol (2011) 1.48
Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther (2007) 1.40
In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther (2006) 1.23
Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis (2006) 1.22
Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther (2011) 1.14
Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis (2006) 1.12
Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann Rheum Dis (2002) 1.11
Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res Ther (2014) 1.04
Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res (2001) 1.02
Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One (2011) 1.02
Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther (2012) 1.01
The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma. Arthritis Res (2000) 1.00
Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther (2009) 0.98
CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res (2002) 0.98
Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther (2005) 0.97
The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One (2014) 0.93
Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis. Ann Rheum Dis (2005) 0.91
Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis. Medicine (Baltimore) (2013) 0.90
Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res Ther (2007) 0.90
High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. J Neurol (2005) 0.89
Developments in the scientific and clinical understanding of inflammatory myopathies. Arthritis Res Ther (2008) 0.88
Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther (2013) 0.88
Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol (2012) 0.86
Clinical features of inflammatory myopathies and their association with malignancy: a systematic review in asian population. ISRN Rheumatol (2013) 0.86
Common and specific associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies in systemic lupus erythematosus. ScientificWorldJournal (2013) 0.85
Role of non-immune mechanisms of muscle damage in idiopathic inflammatory myopathies. Arthritis Res Ther (2012) 0.85
Alternative splicing factor ASF/SF2 is down regulated in inflamed muscle. J Clin Pathol (2006) 0.83
Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin Exp Immunol (2002) 0.83
Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis. J Autoimmune Dis (2009) 0.82
Autoantibodies produced at the site of tissue damage provide evidence of humoral autoimmunity in inclusion body myositis. PLoS One (2012) 0.80
Caspase-mediated cleavage of the exosome subunit PM/Scl-75 during apoptosis. Arthritis Res Ther (2007) 0.79
Polymyositis and dermatomyositis: Disease spectrum and classification. Indian J Dermatol (2012) 0.78
Brief report: antisynthetase syndrome-associated myocarditis. J Card Fail (2014) 0.78
Serological epitope profile of anti-Ro52-positive patients with systemic autoimmune rheumatic diseases. Arthritis Res Ther (2015) 0.77
Rare association of antisynthetase syndrome and Kennedy's disease. Clin Rheumatol (2008) 0.77
[PM-Scl antibody positive systemic sclerosis associated with inclusion-body myositis]. Z Rheumatol (2005) 0.77
Anti-signal recognition particle autoantibody ELISA validation and clinical associations. Rheumatology (Oxford) (2014) 0.76
Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis. Rheumatol Int (2016) 0.76
Signal recognition particle (SRP) positive myositis in a patient with cryptogenic organizing pneumonia (COP). Rheumatol Int (2009) 0.76
Less specific myositis autoantibodies? Ann Rheum Dis (2001) 0.75
Development of myasthenia gravis 8 years after interstitial lung disease associated with antisynthetase (anti-EJ antibody) syndrome. Clin Case Rep (2016) 0.75
Inflammatory myopathy with anti-SRP antibodies: case series of a South Australian cohort. Clin Rheumatol (2014) 0.75
[Dermatomyositis-specific antibodies]. Z Rheumatol (2015) 0.75
Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India. Rheumatol Int (2017) 0.75
Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology. Clin Rev Allergy Immunol (2017) 0.75
A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity. Rheumatol Int (2017) 0.75
[New aspects on the pathogenesis of myositis]. Z Rheumatol (2013) 0.75
Polymyositis and dermatomyositis (first of two parts). N Engl J Med (1975) 18.52
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum (2000) 8.64
Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev (1999) 7.58
Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet (1999) 5.70
The yeast exosome and human PM-Scl are related complexes of 3' --> 5' exonucleases. Genes Dev (1999) 4.95
Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med (1991) 4.14
A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) (1991) 4.01
Characterization of the CHD family of proteins. Proc Natl Acad Sci U S A (1997) 3.76
Knowing when not to stop: selenocysteine incorporation in eukaryotes. Trends Biochem Sci (1996) 3.72
Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum (1995) 2.67
Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol (1997) 2.05
Antibody to signal recognition particle in polymyositis. Arthritis Rheum (1990) 1.74
Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol (1985) 1.71
The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum (1985) 1.62
Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A (1992) 1.58
The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum (1995) 1.44
Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum (1986) 1.43
Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med (1986) 1.40
Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum (1996) 1.39
Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum (1985) 1.35
Dissociation of immune responses to the SS-A (Ro) 52-kd and 60-kd polypeptides in systemic lupus erythematosus and Sjögren's syndrome. Arthritis Rheum (1990) 1.28
Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum (1997) 1.21
Cloning and characterization of the cDNA coding for a polymyositis-scleroderma overlap syndrome-related nucleolar 100-kD protein. J Exp Med (1992) 1.20
Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen. J Clin Invest (1995) 1.18
Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am (1994) 1.17
Intracellular localization and nucleocytoplasmic transport of Ro RNP components. Eur J Cell Biol (1997) 1.17
The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun (1999) 1.15
Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis (1993) 1.14
Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum (1992) 1.11
Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum (1992) 1.07
Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis. J Rheumatol (1998) 1.07
Multiplicity of antibodies in myositis sera. Arthritis Rheum (1984) 1.05
Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr Opin Rheumatol (1998) 1.03
Cloning of a complementary DNA coding for the 100-kD antigenic protein of the PM-Scl autoantigen. J Clin Invest (1992) 1.03
Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol (1999) 1.01
The U1 snRNP complex: an autoantigen in connective tissue diseases. An update. Clin Exp Rheumatol (1997) 0.99
The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis (2000) 0.98
Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. Arthritis Rheum (1991) 0.98
Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle. J Immunol (1987) 0.92
Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum (1996) 0.91
Analysis of the specificity of anti-PM-Scl autoantibodies. Arthritis Rheum (1994) 0.87
Clinical and serologic features of patients with polymyositis or dermatomyositis. Can Med Assoc J (1985) 0.86
Frequent occurrence of anti-tRNA(His) autoantibodies that recognize a conformational epitope in sera of patients with myositis. Arthritis Rheum (1998) 0.84
Immune aspects of myositis. Curr Opin Rheumatol (1992) 0.82
Structure and function of signal recognition particle (SRP). Mol Biol Rep (1993) 0.82
A clinical, serological, and histopathological study of myositis patients with and without anti-RNP antibodies. Semin Arthritis Rheum (1992) 0.82
Genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol (1996) 0.81
Humoral immunity and immunogenetics in the idiopathic inflammatory myopathies. Curr Opin Rheumatol (1991) 0.80
Presence of the anti-Jo-1 autoantibody excludes inclusion body myositis. Ann Neurol (1998) 0.80
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell (1998) 7.37
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Immunosuppressive effects of apoptotic cells. Nature (1997) 7.03
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum (1996) 6.88
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med (1988) 4.69
Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis (2003) 4.36
Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum (2001) 4.06
Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 3.61
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum (1998) 3.41
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Unemployment and mortality--a longitudinal prospective study on selection and causation in 49321 Swedish middle-aged men. J Epidemiol Community Health (2010) 3.13
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res (1994) 2.96
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis (2010) 2.52
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Underreporting of energy intake in repeated 24-hour recalls related to gender, age, weight status, day of interview, educational level, reported food intake, smoking habits and area of living. Public Health Nutr (2001) 2.37
Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis (2004) 2.35
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis (2008) 2.35
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis (1992) 2.05
Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am Rev Respir Dis (1989) 1.99
An ikaros-containing chromatin-remodeling complex in adult-type erythroid cells. Mol Cell Biol (2000) 1.97
Socioeconomic status and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis (2005) 1.96
An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum (2005) 1.96
Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) (2001) 1.96
In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum (1997) 1.95
Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood (1998) 1.93
Activated T cells in vivo and in vitro: divergence in expression of Tac and Ia antigens in the nonblastoid small T cells of inflammation and normal T cells activated in vitro. J Immunol (1984) 1.87
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 1.84
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis (2001) 1.78
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol (2001) 1.72
Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med (1988) 1.72
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) (2003) 1.71
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Joint and connective tissue ultrasonography--a rheumatologic bedside procedure? A German experience. Arthritis Rheum (1995) 1.66
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum (2008) 1.65
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int (1995) 1.63
Immunological changes in human skeletal muscle and blood after eccentric exercise and multiple biopsies. J Physiol (2000) 1.63
Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis (2001) 1.63
The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol (2001) 1.62
The prevalence of pain in a general population. The results of a postal survey in a county of Sweden. Pain (1989) 1.59
SLE--a disease of clearance deficiency? Rheumatology (Oxford) (2005) 1.59
A C-terminally-anchored Golgi protein is inserted into the endoplasmic reticulum and then transported to the Golgi apparatus. Proc Natl Acad Sci U S A (1995) 1.59
Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis (2006) 1.54
Single-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum (1993) 1.53
Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. J Immunol (1990) 1.52
Anti-heart and anti-intercalated disk autoantibodies: evidence for autoimmunity in idiopathic recurrent acute pericarditis. Heart (2010) 1.51
Studies on experimental autoimmune thymitis in guinea-pigs. Clin Exp Immunol (1969) 1.50
Increased levels of antibodies to heat shock proteins with increasing age in Mrl/Mp-lpr/lpr mice. Br J Rheumatol (1995) 1.48
Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol (1995) 1.48
Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. Eur J Immunol (1992) 1.48
Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2003) 1.48
In vitro and in vivo effect of glucocorticoids on IgE and IgG subclass secretion. Clin Exp Allergy (1994) 1.47
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
On the pathogenesis of galactosamine hepatitis. Indications of extrahepatocellular mechanisms responsible for liver cell death. Virchows Arch B Cell Pathol (1978) 1.46
Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. Transplantation (2001) 1.46
Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum (1991) 1.45
Externally assessed psychosocial work characteristics and diagnoses of anxiety and depression. Occup Environ Med (2008) 1.45
Quantitative scoring of an interferon-gamma assay for differentiating active from latent tuberculosis. Eur Respir J (2007) 1.45
Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun (1991) 1.45
Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) (2002) 1.45
The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum (1995) 1.44
CD4 positive peripheral T cells from patients with systemic lupus erythematosus (SLE) are clonally expanded. Lupus (2001) 1.44
Autoimmune diseases--at the molecular level. Immunol Today (1993) 1.42
An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford) (2006) 1.42
Collaboration between developing and developed countries and between developing countries in occupational health research and surveillance. Scand J Work Environ Health (1999) 1.41
Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus (2002) 1.41
Normal serum activities of liver enzymes in Swedish paint industry workers with heavy exposure to organic solvents. Br J Ind Med (1985) 1.39
Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis (2002) 1.39
Cognitive functions in depressive disorders: evidence from a population-based study. Psychol Med (2004) 1.38
The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis (2007) 1.37
A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J Autoimmun (1989) 1.36
Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J Rheumatol (1994) 1.35
Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol (1992) 1.34
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum (2008) 1.34
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis (2002) 1.33
Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis (2004) 1.32
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis (2006) 1.32
Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis (2004) 1.32
Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol (1997) 1.32
Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol (2000) 1.32